6 research outputs found
Π ΠΌΠ΅ΡΡΠ½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π°ΠΊΠ½Π΅
The review summarizes and systematizes data accumulated in the world research literature, which are related to the role of P. acnes in the pathogenesis of acne, its microbiology and antibacterial resistance; it also examines antibacterial drugs for the external therapy of acne and recommendations for their use.Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½Ρ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½Π½ΡΠ΅ Π² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ Π½Π°ΡΡΠ½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ, ΠΊΠ°ΡΠ°ΡΡΠΈΠ΅ΡΡ ΡΠΎΠ»ΠΈ
P. acnes Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ ΡΠ³ΡΠ΅ΠΉ, Π΅Π³ΠΎ ΠΌΠΈΠΊΡΠΎΠ±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΠΈ, ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ Π°Π½ΡΠΈΠ±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΠ΅
ΡΡΠ΅Π΄ΡΡΠ²Π° Π΄Π»Ρ Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠ³ΡΠ΅ΠΉ ΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ ΠΏΠΎ ΠΈΡ
ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π½Π΅ΠΈΠ½ΡΠ΅ΡΠ²Π΅Π½ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ BODYGUARD Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ
Introduction. Currently there is insufficient data regarding routine use of various topical treatments for plaque psoriasis outside from randomized clinical trials, their efficacy, cost-effectiveness and perception by dermatologists and patients. The primary rationale for this study was local data generation for the long-term (up to 52 weeks) treatment of body psoriasis in Russian patientsβ population with fixed-dose combination of calcipotriol and betamethasone dipropionate in the formulation of gel to evaluate patientβs adherence to the therapy and their satisfaction level.Materials and methods. Primary study objectives were evaluation of the long-term (up to 52 weeks) treatment success of body psoriasis with fixed-dose combination of calcipotriol and betamethasone dipropionate gel by Physician (Physician Psoriasis Global Assessment (PsGA, 5-point scale)) and by patient (Patientβs Global Psoriasis Assessment (PaGA, 5-point scale) and overall patientβs satisfaction using 4-point scale), patientβs satisfaction with the treatment via Patient Preference Questionnaire (PPQ), patientsβ adherence to the treatment using Questionnaire of Adherence, impact of treatment on patientsβ quality of life using DLQI questionnaire, and patientsβ readiness to buy topical therapy product out of pocket based on consumption of the study medication during follow up period. Patients received treatment with topical calcipotriol/betamethasone gel which was prescribed as a routine medication without connection to the study purposes for up to 8 weeks. After the treatment patients were followed up for up to 52 weeks; during this period they were allowed to continue treatment with either maintenance or intermittent schedule. 128 dermatologists participated in the study, 612 patients with body plaque psoriasis (mean age 42.0 Β± 13.30 years) were included; from this sample 544 (88.7 %) patients underwent follow up.Results. All 612 included patients received initial therapy with calcipotriol/betamethasone gel; during follow-up period 410 (76.1 %) patients received treatment by any schedule (out of 539 assessed). Overall treatment success based on average PsGA score: initially 3.0 Β± 0.54, after appr.8 weeks β 1.3 Β± 0.80 and after appr.52 week 1.1 Β± 0.96; based on average PaGA score β initially 3.0 Β± 0.54, after appr.8 weeks β 1.5 Β± 0.88 and after appr.52 week 1.1 Β± 0.99. The proportion of patients which described their overall satisfaction with the treatment as βsatisfiedβ or βabsolutely satisfiedβ equaled 92.3 % at visit at the end of active treatment and 93.1 % at visit up to 52 weeks afterwards. Also at visit at the end of active treatment 93.8 % of patients considered their current treatment as βmore effectiveβ than previous topical treatment they received. Patientsβ adherence to the therapy was satisfactory β average application rate of calcipotriol/betamethasone (should be applied daily) gel at the last 7 days of treatment at visit at the end of active treatment comprised 5.6 Β± 2.6 days, which means that 6 out of 7 days of the treatment were not missed. Initial DLQI score was 13.6 Β± 5.95 and it reduced down to 3.89 Β± 5.95 at visit at the end of active treatment (p 0.001) reflecting positive impact of successful therapy on patientsβ psychosocial wellbeing.Discussion. Results of this study provides additional information regarding routine topical therapy in patients with plaque psoriasis. These findings demonstrate that the therapy of body plaque psoriasis with calcipotriol/betamethasone gel is effective both in short and long term according to the evaluation by dermatologists and by patients themselves. This therapy provides good rate of adherence and patientsβ satisfaction as well as affects positively at patientsβ psychosocial wellbeing assessed by DLQI score.Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π‘Π΅Π³ΠΎΠ΄Π½Ρ ΡΡΡΠ΅ΡΡΠ²ΡΠ΅Ρ Π΄Π΅ΡΠΈΡΠΈΡ Π΄Π°Π½Π½ΡΡ
ΠΏΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±Π»ΡΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² ΠΏΠΎΠ²ΡΠ΅Π΄Π½Π΅Π²Π½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Π²ΡΠ°ΡΠ΅ΠΉ-Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ², ΠΊΠΎΡΠΎΡΡΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ»ΠΈ Π±Ρ ΠΎΡΠ΅Π½ΠΈΡΡ ΠΈΡ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ, ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ½ΠΎΡΡΡ ΠΈ Π²ΠΎΡΠΏΡΠΈΡΡΠΈΠ΅ Π²ΡΠ°ΡΠ°ΠΌΠΈ ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ. ΠΠ°Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ Ρ ΡΠ΅Π»ΡΡ Π²ΠΎΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ±Π΅Π»Π° ΠΈ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΎ Π½Π° ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ (Π΄ΠΎ 52 Π½Π΅Π΄Π΅Π»Ρ) Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΏΡΠΎΡΠΈΠ°Π·ΠΎΠΌ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ ΠΊΠ°Π»ΡΡΠΈΠΏΠΎΡΡΠΈΠΎΠ»Π° ΠΈ Π±Π΅ΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΈΠΏΡΠΎΠΏΠΈΠΎΠ½Π°ΡΠ° Π² Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠ΅ Π³Π΅Π»Ρ Ρ Π°ΠΊΡΠ΅Π½ΡΠΎΠΌ Π½Π° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ΅ΡΠ²ΠΈΡΠ½ΡΠΌΠΈ ΡΠ΅Π»ΡΠΌΠΈ Π±ΡΠ»ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ (Π΄ΠΎ 52 Π½Π΅Π΄Π΅Π»Ρ) Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΡΠΎΡΠΈΠ°Π·Π° ΡΠ΅Π»Π° ΡΠΈΠΊΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠ΅ΠΉ ΠΊΠ°Π»ΡΡΠΈΠΏΠΎΡΡΠΈΠΎΠ»Π° ΠΈ Π±Π΅ΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΈΠΏΡΠΎΠΏΠΈΠΎΠ½Π°ΡΠ° Π² Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΠ΅ Π³Π΅Π»Ρ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ 5-Π±Π°Π»Π»ΡΠ½ΡΡ
ΡΠΊΠ°Π» ΠΎΡΠ΅Π½ΠΊΠΈ Π²ΡΠ°ΡΠΎΠΌ (PsGA) ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ (PΠ°GA), Π° ΡΠ°ΠΊΠΆΠ΅ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½Π½ΠΎΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ (4-Π±Π°Π»Π»ΡΠ½Π°Ρ ΡΠΊΠ°Π»Π° ΠΈ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ ΠΏΡΠ΅Π΄ΠΏΠΎΡΡΠ΅Π½ΠΈΠΉ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°), ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΎΡΠ΅Π½ΠΊΠ° ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ (ΠΈΠ½Π΄Π΅ΠΊΡ DLQI) ΠΈ Π³ΠΎΡΠΎΠ²Π½ΠΎΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ°ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ Π·Π° ΡΠ²ΠΎΠΉ ΡΡΠ΅Ρ. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Π½Π°Π·Π½Π°ΡΠ°Π»ΠΎΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΏΠΎΠ²ΡΠ΅Π΄Π½Π΅Π²Π½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠΈ Π±Π΅Π· ΡΠ²ΡΠ·ΠΈ Ρ Π΄Π°Π½Π½ΡΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ, ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΡΡΠ°ΡΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π³Π΅Π»Π΅ΠΌ ΠΊΠ°Π»ΡΡΠΈΠΏΠΎΡΡΠΈΠΎΠ»Π° ΠΈ Π±Π΅ΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΈΠΏΡΠΎΠΏΠΈΠΎΠ½Π°ΡΠ° ΡΠΎΡΡΠ°Π²Π»ΡΠ»Π° Π΄ΠΎ 8 Π½Π΅Π΄Π΅Π»Ρ. Π ΡΠ°ΠΌΠΊΠ°Ρ
Π²ΡΠΎΡΠΎΠ³ΠΎ ΡΡΠ°ΠΏΠ° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ Π·Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ°Π»ΠΎΡΡ Π΄ΠΎ 52 Π½Π΅Π΄Π΅Π»Ρ, Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΡΡ
ΠΎΠ½ΠΈ ΠΌΠΎΠ³Π»ΠΈ ΠΏΠΎΠ»ΡΡΠ°ΡΡ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΈΠ²Π°ΡΡΠ΅ΠΉ ΠΈΠ»ΠΈ ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅ΠΉ ΡΡ
Π΅ΠΌΠ΅. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ 128 Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΈ 612 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΠ· ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΎΡΠΎΠ΄ΠΎΠ² Π Π€, ΠΈΠ· ΡΡΠΎΠΉ Π³ΡΡΠΏΠΏΡ 544 (88,7 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΏΡΠΎΡΠ»ΠΈ ΡΡΠ°ΠΏ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΠ΅ 612 Π²ΠΊΠ»ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ ΡΡΠ°ΡΡΠΎΠ²ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π³Π΅Π»Π΅ΠΌ ΠΊΠ°Π»ΡΡΠΈΠΏΠΎΡΡΠΈΠΎΠ»Π° ΠΈ Π±Π΅ΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° Π΄ΠΈΠΏΡΠΎΠΏΠΈΠΎΠ½Π°ΡΠ°; Π² ΡΠ°ΠΌΠΊΠ°Ρ
ΠΏΠ΅ΡΠΈΠΎΠ΄Π° ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠ΅Π³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎ Π»ΡΠ±ΠΎΠΉ ΡΡ
Π΅ΠΌΠ΅ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 410 (76,1 %) ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΠ· 539, ΠΏΠΎΠ΄Π»Π΅ΠΆΠ°ΡΠΈΡ
ΠΎΡΠ΅Π½ΠΊΠ΅. ΠΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΎΠ±ΡΠ΅ΠΉ ΡΡΠΏΠ΅ΡΠ½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ Π²ΡΠ°ΡΠΎΠΌ (PsGA) ΡΠΎΡΡΠ°Π²ΠΈΠ»: ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ β 3,0 Β± 0,54, ΡΠ΅ΡΠ΅Π· ~ 8 Π½Π΅Π΄Π΅Π»Ρ β 1,3 Β± 0,80 ΠΈ ΡΠ΅ΡΠ΅Π· ~ 52 Π½Π΅Π΄Π΅Π»ΠΈ β 1,1 Β± 0,96; Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΌ (PΠ°GA): ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ β 3,0 Β± 0,54, ΡΠ΅ΡΠ΅Π· ~ 8 Π½Π΅Π΄Π΅Π»Ρ β 1,5 Β± 0,88 ΠΈ ΡΠ΅ΡΠ΅Π· ~ 52 Π½Π΅Π΄Π΅Π»ΠΈ β 1,1 Β± 0,99. ΠΠΎΠ»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΡΠΊΠ°Π·Π°Π²ΡΠΈΡ
, ΡΡΠΎ ΠΎΠ½ΠΈ Β«ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½ΡΒ» ΠΈΠ»ΠΈ Β«Π°Π±ΡΠΎΠ»ΡΡΠ½ΠΎ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½ΡΒ» Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ, ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 92,3 % ΠΏΠΎΡΠ»Π΅ ΡΡΠ°ΡΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ 93,1 % Π½Π° Π²ΠΈΠ·ΠΈΡΠ΅ ΡΠ΅ΡΠ΅Π· ~ 52 Π½Π΅Π΄Π΅Π»ΠΈ. Π’Π°ΠΊΠΆΠ΅ Π½Π° Π²ΠΈΠ·ΠΈΡΠ΅ ΠΏΠΎΡΠ»Π΅ ΡΡΠ°ΡΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ 93,8 % ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΡΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΡΡΠΈΡΠ°ΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Β«Π±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌΒ», ΡΠ΅ΠΌ ΡΡΠ΅Π΄ΡΡΠ²Π° Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ, ΠΊΠΎΡΠΎΡΡΠ΅ ΠΎΠ½ΠΈ ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ ΡΠ°Π½Π΅Π΅. ΠΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΡΠ»Π° ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ β ΡΡΠ΅Π΄Π½ΡΡ ΡΠ°ΡΡΠΎΡΠ° Π½Π°Π½Π΅ΡΠ΅Π½ΠΈΠΉ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Π½Π° ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
7 Π΄Π½ΡΡ
ΡΡΠ°ΡΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 5,6 Β± 2,6 Π΄Π½Ρ, Ρ.Π΅. 6 ΠΈΠ· 7 Π΄Π½Π΅ΠΉ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π΅ Π±ΡΠ»ΠΈ ΠΏΡΠΎΠΏΡΡΠ΅Π½Ρ. ΠΠ½Π΄Π΅ΠΊΡ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ DLQI ΠΈΡΡ
ΠΎΠ΄Π½ΠΎ ΡΠΎΡΡΠ°Π²Π»ΡΠ» 13,6 Β± 5,95 Π±Π°Π»Π»Π° ΠΈ ΡΠ½ΠΈΠ·ΠΈΠ»ΡΡ Π΄ΠΎ 3,89 Β± 5,95 ΠΏΠΎΡΠ»Π΅ ΡΡΠ°ΡΡΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ (p 0,001), ΡΡΠΎ Π³ΠΎΠ²ΠΎΡΠΈΡ ΠΎ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠΌ Π²Π»ΠΈΡΠ½ΠΈΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° ΠΏΡΠΈΡ
ΠΎΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ Π±Π»Π°Π³ΠΎΠΏΠΎΠ»ΡΡΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π΄Π°ΡΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π΅Π΄Π΅Π½ΠΈΡ ΠΎ Π½Π°ΡΡΠΆΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π±Π»ΡΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ°Π·Π° Π² ΠΏΠΎΠ²ΡΠ΅Π΄Π½Π΅Π²Π½ΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ Π²ΡΠ°ΡΠ΅ΠΉ-Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΎΠ². ΠΠ½ΠΈ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΡΡ, ΡΡΠΎ Π½Π°ΡΡΠΆΠ½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π³Π΅Π»Π΅ΠΌ ΠΊΠ°Π»ΡΡΠΈΠΏΠΎΡΡΠΈΠΎΠ»Π°/Π±Π΅ΡΠ°ΠΌΠ΅ΡΠ°Π·ΠΎΠ½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π° ΠΊΠ°ΠΊ ΠΏΡΠΈ ΠΊΡΠ°ΡΠΊΠΈΡ
, ΡΠ°ΠΊ ΠΈ ΠΏΡΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΊΡΡΡΠ°Ρ
, Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ Π΄Π΅ΡΠΌΠ°ΡΠΎΠ»ΠΎΠ³Π°ΠΌΠΈ ΠΈ ΡΠ°ΠΌΠΈΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌΠΈ. ΠΡΠΌΠ΅ΡΠ°ΡΡΡΡ Ρ
ΠΎΡΠΎΡΠ°Ρ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ Π²ΡΡΠΎΠΊΠΈΠΉ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΡΠ΄ΠΎΠ²Π»Π΅ΡΠ²ΠΎΡΠ΅Π½Π½ΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° ΠΏΡΠΈΡ
ΠΎΡΠΎΡΠΈΠ°Π»ΡΠ½ΠΎΠ΅ Π±Π»Π°Π³ΠΎΠΏΠΎΠ»ΡΡΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ½Π΄Π΅ΠΊΡΠ° ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΆΠΈΠ·Π½ΠΈ DLQI